Phase I randomized, double-blind, placebo-controlled, single and multiple ascending dose study, to evaluate the safety and tolerability of PL-8177 administered via subcutaneous injection

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs PL 8177 (Primary)
Indications COVID 2019 infections; Inflammatory bowel diseases; Nephritis; Ulcerative colitis; Uveitis
Focus Adverse reactions; First in man

25 Oct 2021 Results assessing safety and pharmacokinetics of PL8177 after subcutaneous (sc) delivery in animals and humans, published in the Drugs in R and D.
08 Nov 2018 Results presented in a Palatin Technologies media release.
08 Nov 2018 Status changed from recruiting to completed, according to a Palatin Technologies media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com